‘Interprotein Corporation Product Pipeline Review - 2016’, provides an overview of the Interprotein Corporation’s pharmaceutical research and development focus

PUNE, INDIA, April 14, 2016 /EINPresswire.com/ -- The report “Interprotein Corporation - Product Pipeline Review - 2016 “provides comprehensive information on the therapeutics under development by Interprotein Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Access a Report Copy @ https://www.wiseguyreports.com/reports/interprotein-corporation-product-pipeline-review-2016 .

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Interprotein Corporation
- The report provides overview of Interprotein Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Interprotein Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Interprotein Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Purchase a 1-User License Copy @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=393573 .

Reasons to buy

- Evaluate Interprotein Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Interprotein Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Interprotein Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Major Point in Table of Content

Interprotein Corporation - Drug Profiles 16
IPC-003 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Small Molecules to Inhibit VEGF for Solid Tumors 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Small Molecule to Inhibit gp130 for Inflammation and Oncology 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Small Molecule to Inhibit IgE for Allergies 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Small Molecules to Inhibit RUNX1 for Acute Myeloid Leukemia 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Synthetic Peptide to Inhibit gp130 for Inflammation and Oncology 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Synthetic Peptides to Antagonize KIR for Oncology 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Synthetic Peptides to Antagonize NKG2A for Oncology 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Synthetic Peptides to Inhibit TIM-3 for Oncology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24

Inquire for more information @ https://www.wiseguyreports.com/enquiry/interprotein-corporation-product-pipeline-review-2016 .

Norah Trent
WiseGuy Research Consultants Pvt. Ltd.
16468459349
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.